Experts note that Democrats are likely to place Trump’s MFN deals under the microscope and vie to reverse sweeping Medicaid cuts following the midterm results.

AbbVie will use the Oxford site to advance treatments for immunological, neurological and oncological diseases.

GEBRO Holding and Spektus Pharma have agreed a global commercialisation partnership for ActraFlex, an extended-release pain management therapy taken twice daily.

Combining longitudinal claims data with deeper inpatient detail supports stronger real-world evidence for life sciences and medical device research.

The FDA has accepted a BLA under its accelerated approval pathway from uniQure for ifezuntirgene inilparvovec to treat Huntington’s disease.

AbbVie has announced a licensing agreement with Beijing-based Brise Pharmaceuticals, which will see the pair work together to progress and potentially commercialise a set of early ...

MVA-BN was originally developed in collaboration with the US Government as a smallpox vaccine. Credit: Bavarian Nordic. Bavarian Nordic has secured a four-year contract from the UK Government to ...

Fresenius and WuXi Biologics will work together to develop up to 37 biosimilar candidates targeting a range of therapeutic areas, giving the German company ample scope to bolster ...

Pelthos Therapeutics has agreed to merge with Castle Creek Biosciences to form a new biotechnology company that will focus on serious diseases affecting the skin.

Inovio has secured accelerated approval from the FDA for Voceryq to minimise the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP).

At IDWeek 2026, Samir K Gupta presented a pooled analysis of the Phase III ISLEND-1 and ISLEND-2 trials evaluating once-weekly ISL/LEN in adults with virologically suppressed HIV.